ArticleGene therapy2009
Subconjunctival gene delivery of the transcription factor GA-binding protein delays corneal neovascularization in a mouse model.
Article in Gene therapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 29 citations in OpenAlex.
- Review
- Co-assembling de novo designed peptide with high-payload drug protein for noninvasive treatment of corneal neovascularization.International journal of pharmaceutics: X · 2025Article
- Genetic Basis of Non-Syndromic Childhood Glaucoma Associated with Anterior Segment Dysgenesis: A Narrative Review.Pharmaceuticals (Basel, Switzerland) · 2025Review
- GABPα inhibits tumor progression and angiogenesis via a novel 18-bp indel withinCancer biomarkers : section A of Disease markers · 2024Article
- Unraveling the Molecular Mechanisms of SIRT7 in Angiogenesis: Insights from Substrate Clues.International journal of molecular sciences · 2024Review
- Corneal gene therapy: Structural and mechanistic understanding.The ocular surface · 2023Article
- Cell-specific expression of theFrontiers in molecular biosciences · 2023Article
- Gene Therapy in the Anterior Eye Segment.Current gene therapy · 2022Review
- An Update on Novel Ocular Nanosystems with Possible Benefits in the Treatment of Corneal Neovascularization.International journal of nanomedicine · 2022Review
- Comparison of the Therapeutic Efficacies of Topical Rivoceranib and Topical Bevacizumab in a Murine Model of Corneal Neovascularization.Medicina (Kaunas, Lithuania) · 2019Article
- Regulatory mechanisms of Robo4 and their effects on angiogenesis.Bioscience reports · 2019Review
- Pharmaceutical Development of AAV-Based Gene Therapy Products for the Eye.Pharmaceutical research · 2018Review
- Gene therapy in the cornea: 2005--present.Progress in retinal and eye research · 2012Review
- Republished review: Gene therapy for ocular diseases.Postgraduate medical journal · 2011Article
- Activation of endothelial roundabout receptor 4 reduces the severity of virus-induced keratitis.Journal of immunology (Baltimore, Md. : 1950) · 2011Article
- Gene therapy for ocular diseases.The British journal of ophthalmology · 2011Review
- Strategies for local gene therapy of corneal allograft rejection.Middle East African journal of ophthalmologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Corneal neovascularization can reduce visual acuity. GA-binding protein (GABP) is a transcription factor that regulates the expression of target genes including vascular endothelial growth factor (VEGF) and roundabout4 (Robo4), which participate in pathologic angiogenesis. We assessed whether intraocular injection of the GABP gene affects the growth of new corneal blood vessels in a mouse ocular neovascularization model. Transfection of human GABPalpha and GABPbeta gene (GABPalpha/beta) into human conjunctival epithelial cells resulted in decreased VEGF and Robo4 expression. Three groups of mice underwent chemical and mechanical denudation of the corneal epithelium. Subsequently, two groups were administered subconjunctival injection of lipoplexes carrying plasmid DNA encoding for human GABPalpha/beta or an empty plasmid DNA at 1-week intervals. The third group served as an experimental control. In vivo delivery of human GABPalpha/beta into mouse neovascularized cornea reduced VEGF and Robo4 gene expression. Biomicroscopic examination showed that, at 1 week after one or two injections, GABPalpha/beta-treated eyes had significantly less neovascularized corneal area than did eyes treated with the empty vector. Histologic examination showed significantly less vascularized area and fewer blood vessels in the GABP-treated group at 1 week after injections. However, these angiosuppressive effects were weakened at 2 weeks after injections. Our results indicate that subconjunctival GABP gene delivery delays corneal neovascularization for up to 2 weeks in a mouse model of deliberate corneal injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.